We are joined by European Endocrinology Editorial Board member Professor Chantal Mathieu to discuss the most important advances in insulin therapies for type 1 and type 2 diabetes.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA
Questions:
1. What have been the most exciting recent developments in insulin therapy for type 1 diabetes? (0:05)
2. What adjunctive glucose-lowering agents are most useful in patients with type 1 diabetes? (1:22)
3. What are the most important considerations when choosing a glucose-lowering therapy for a patient with type 2 diabetes? (3:43)
4. What do you anticipate will be the next major breakthrough in type 2 diabetes? (5:23)
5. What are your highlights of the 2019 ADA meeting? (6:15)
Chantal Mathieu has no conflicts of interest to declare in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
